Drug Profile
Research programme: cyclophilin inhibitors - Cypralis/Gilead
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Gilead Sciences; Selcia
- Developer Cypralis Limited; Gilead Sciences; Selcia
- Class Neuroprotectants; Small molecules
- Mechanism of Action Cyclophilin D inhibitors; Peptidylprolyl isomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver disorders; Neurodegenerative disorders
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in United Kingdom
- 28 Feb 2022 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA
- 28 Apr 2018 No recent reports of development identified for preclinical development in Liver-disorders in United Kingdom